Matthew Vogt, MD, PhD, was awarded an R01 from NIAID to generate new monoclonal antibodies in hopes of informing pan-enterovirus vaccines.
Matthew Vogt, MD, PhD, assistant professor of Pediatrics in the Division of Infectious Diseases and of Microbiology & Immunology, has been granted an R01 from the National Institute of Allergy and Infectious Diseases (NIAID).
The 5-year, $3.14 million grant is in support of the project “Human Antibody Cross-Reactivity in Non-Polio Enteroviruses”. The project aims to define the degree to which humans generate antibody responses that are reactive to different enteroviruses, allowing prioritization of vaccine efforts to those viruses with poorer natural response.
Human monoclonal antibodies isolated during these studies will help determine which structural parts of these viruses generate the most broadly reactive antibodies, allowing vaccine design to focus on authentically replicating these structures. Further, the monoclonal antibodies themselves have potential for use in prevention or treatment of enterovirus infections causing disease.
Vogt is an Assistant Professor in the Departments of Pediatrics and Microbiology & Immunology. He is a member of the Children’s Research Institute, where his research program is focused the pathogenesis of respiratory viral diseases of childhood and the humoral immune response to these diseases.